Citations

Showing 10 of 108119 citations.

Nascent Lung Organoids Reveal Epithelium- and Bone Morphogenetic Protein–mediated Suppression of Fibroblast Activation
Tan, Qi , Meridew, Jeffrey A., Jones, Dakota L. , Haak, Andrew J. , Sicard, Delphine , Ligresti, Giovanni , Tschumperlin, Daniel J. , Ma, Xiao Yin, Xiao, Yin , Liu, Wei Yong

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | May 3, 2019 | Volume: 61 | Issue: 5 | Pages: 607-619

10.1165/rcmb.2018-0390oc | PMID 31050552 Get It

Abstract Reciprocal epithelial–mesenchymal interactions are pivotal in lung development, homeostasis, injury, and repair. Organoids have been used to investigate such interactions, but with a major focus on epithelial responses to mesenchyme and less attention to epithelial effects on mesenchyme. In the present study, we used nascent organoids composed of human and mouse lung epithelial and mesenchymal cells to demonstrate that healthy lung epithelium dramatically represses transcriptional, contractile, and matrix synthetic functions of lung fibroblasts. Repression of fibroblast activation requires signaling via the bone morphogenetic protein (BMP) pathway. BMP signaling is diminished after epithelial injury in vitro and in vivo, and exogenous BMP4 restores fibroblast repression in injured organoids. In contrast, inhibition of BMP signaling in healthy organoids is sufficient to derepress fibroblast matrix synthetic function. Our results reveal potent repression of fibroblast activation by healthy lung epithelium and a novel mechanism by which epithelial loss or injury is intrinsically coupled to mesenchymal activation via loss of repressive BMP signaling.
Development of an Objective Model to Define Near-Term Risk of Ileocecal Resection in Patients with Terminal Ileal Crohn Disease
Alsughayer, Ahmad, Petersen, M. , Bruining, David H. , Bartlett, David J. , Mathis, Kellie L. , Petersen, Molly, Grass, Fabian , Fletcher, Joel G. , Lightner, Amy L.

Mayo Clinic

Inflammatory Bowel Diseases | May 3, 2019 | Volume: 25 | Issue: 11 | Pages: 1845-1853

10.1093/ibd/izz079 | PMID 31050733 Get It

Abstract Background The decision to either escalate medical therapy or proceed to ileocecal resection (ICR) in patients with terminal ileal Crohn disease (CD) remains largely subjective. We sought to develop a risk score for predicting ICR at 1 year from computed tomography or magnetic resonance enterography (CTE/MRE). Methods We conducted a retrospective cohort study including all consecutive adult (> 18 years) patients with imaging findings of terminal ileal CD (Montreal classification: B1, inflammatory predominant; B2, stricturing; or B3, penetrating) on CTE/MRE between January 1, 2016, and December 31, 2016. The risk for ICR at 6 months and at 1 year of CTE/MRE and risk factors associated with ICR, including demographics, CD-specific immunosuppressive therapeutics, and disease presentation at the time of imaging, were determined. Results Of 559 patients, 121 (21.6%) underwent ICR during follow-up (1.4 years [IQR 0.21–1.64 years]); the risk for ICR at 6 months and at 1 year was 18.2% (95% CI 14.7%–21.6%) and 20.5% (95% CI 16.8%–24.1%), respectively. Multivariable analysis revealed Montreal classification (B2, hazard ratio [HR] 2.73, and B3, HR 6.80, both P < 0.0001), upstream bowel dilation (HR 3.06, P < 0.0001), and younger age (19–29 years reference, 30–44 years, HR 0.83 [P = 0.40]; 45–59 years, HR 0.58 [P = 0.04], and 60+ years, HR 0.45 [P = 0.01]) to significantly increase the likelihood of ICR. A predictive nomogram for interval ICR was developed based on these significant variables. Conclusions The presence of CD strictures, penetrating complications, and upstream bowel dilation on CTE/MRE, combined with young age, significantly predict ICR. The suggested risk model may facilitate objective therapeutic decision-making.
The effects of cigarette smoking extracts on cell cycle and tumor spread: novel evidence
Croghan, Ivana T. , Pezzuto, Aldo , Citarella, Fabrizio , Tonini, Giuseppe

Mayo Clinic

Future Science OA | May 3, 2019 | Volume: No volume available | Issue: No issue available | Pages: FSO394

10.4155/fsoa-2019-0017 Get It

The Effect of Genetically Guided Mathematical Prediction and the Blood Pressure Response to Pharmacotherapy in Hypertension Patients
Kelley, Eli F. , Olson, Thomas P. , Curry, Timothy B. , Sprissler, Ryan , Snyder, Eric M.

Mayo Clinic

Clinical Medicine Insights: Cardiology | May 3, 2019 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/1179546819845883 | PMID 31105432 Get It

Purpose: The purpose of this study was to determine the effectiveness of a simple algorithm to mathematically predict a patients’ response to blood pressure (BP) therapy using functional genes in the 3 major organ systems involved in hypertension. Methods: Eighty-six patients with controlled hypertension completed 1 study visit consisting of a buccal swab collection, measurement of office BP, and a medical chart review for BP history. Genes in the analysis included 14 functional alleles in 11 genes. These genotypes were mathematically summed per organ system to determine whether a patient would likely respond to target therapy. Results: Patients recommended to and taking a diuretic had significantly higher rates of control (<120/<80) than patients recommended but not taking this drug class (0.2 ± 0.1 and 0.03 ± 0.03, respectively). Furthermore, there was a difference between patients genetically recommended and taking an angiotensin receptor blocker (ARB) vs patients recommended but not taking an ARB for the lowest diastolic blood pressure (DBP) and mean arterial pressure (MAP) recorded in the past 2 years (DBP = 66.2 ± 2.9 and 75.3 ± 1.7, MAP = 82.3 ± 2.8 and 89.3 ± 1.5, respectively). In addition, there was a nonsignificant trend for greater reductions in ΔSBP, ΔDBP, and ΔMAP in patients on recommended drug class for beta-blockers, diuretics, and angiotensin II receptor blockers vs patients not on these classes. Conclusion: The present study suggests that simple mathematical weighting of functional genotypes known to control BP may be ineffective in predicting control. This study demonstrates the need for a more complex, weighted, multigene algorithm to more accurately predict BP therapy response.
The Gene Sculpt Suite: a set of tools for genome editing
Mann, Carla M. , Martínez‐Gálvez, Gabriel , Welker, Jordan M. , Wierson, Wesley A. , Ata, Hirotaka , Almeida, Maira P. , Essner, Jeffrey J. , McGrail, Maura , Ekker, Stephen C. , Ekker, Stephen C , McGrail, Maura , Essner, Jeffrey , Clark, Karl J. , Dobbs, Drena L

Mayo Clinic

Nucleic Acids Research | May 3, 2019 | Volume: 47 | Issue: W1 | Pages: W175-W182

10.1093/nar/gkz405 | PMID 31127311 Get It

Abstract The discovery and development of DNA-editing nucleases (Zinc Finger Nucleases, TALENs, CRISPR/Cas systems) has given scientists the ability to precisely engineer or edit genomes as never before. Several different platforms, protocols and vectors for precision genome editing are now available, leading to the development of supporting web-based software. Here we present the Gene Sculpt Suite (GSS), which comprises three tools: (i) GTagHD, which automatically designs and generates oligonucleotides for use with the GeneWeld knock-in protocol; (ii) MEDJED, a machine learning method, which predicts the extent to which a double-stranded DNA break site will utilize the microhomology-mediated repair pathway; and (iii) MENTHU, a tool for identifying genomic locations likely to give rise to a single predominant microhomology-mediated end joining allele (PreMA) repair outcome. All tools in the GSS are freely available for download under the GPL v3.0 license and can be run locally on Windows, Mac and Linux systems capable of running R and/or Docker. The GSS is also freely available online at www.genesculpt.org.
Catalyzing Research to Optimize Cancer Survivors’ Participation in Work and Life Roles
Newman, Robin , Radomski, Mary Vining , Pergolotti, Mackenzi , Voelbel, Gerald T. , Moor, Janet S. de , Nitkin, Ralph, Daniels, Elvan, Braveman, Brent , Walker, Rae , Campbell, Scott E., Lawlor, Mary , King, Allison A. , Ness, Kirsten K. , Lyons, Kathleen Doyle , King, Allison A , Alfano, Catherine M. , Wolf, Timothy , Sleight, Alix G. , Bryant, Ashley Leak , Williams, Grant R. , Winters‐Stone, Kerri M. , Cheville, Andrea , Campbell, Scott E., Srivastava, Piyush, Ness, Kirsten K

Mayo Clinic

OTJR: Occupational Therapy Journal of Research | May 3, 2019 | Volume: 39 | Issue: 4 | Pages: 189-196

10.1177/1539449219844749 | PMID 31046601 Get It

Participation refers to a state of health in which a person is able to fully engage in roles and life situations. Adults living with and beyond cancer often report persistent participation restrictions that affect their productivity and quality of life. The American Occupational Therapy Foundation convened a group of scientists from seven different disciplines in a Planning Grant Collective (PGC) to stimulate research to identify scalable ways to preserve and optimize participation among cancer survivors. Participants identified challenges, prioritized solutions, and generated novel research questions that move beyond symptom and impairment mitigation as outcomes to identify interventions that improve participation in roles and life situations. This article summarizes the PGC discussion and recommendations regarding three challenges: (a) the dynamic and multi-faceted nature of participation, (b) a need to integrate the concept of participation within the culture of oncology, and (c) identification of priority areas in which new lines of research regarding participation would be most impactful.
Neuromuscular transmission defects in myopathies
Liewluck, Teerin , Laughlin, Ruple S. , Litchy, William J. , Milone, Margherita , Liewluck, T

Mayo Clinic

Muscle & Nerve | May 3, 2019 | Volume: 60 | Issue: 1 | Pages: No page available

10.1002/mus.26503 | PMID 31050017 Get It

Gastrointestinal Mastocytosis: A Potential Diagnostic Pitfall to Be Aware
Zanelli, Magda , Pai, Rish K. , Zorzi, Maria Grazia, Zizzo, Maurizio , Martino, Giovanni , Parisi, Alice, Marco, Loredana De , Annessi, Valerio, Ascani, Stefano , Morelli, Luca

Mayo Clinic

International Journal of Surgical Pathology | May 3, 2019 | Volume: 27 | Issue: 6 | Pages: 643-646

10.1177/1066896919846648 | PMID 31046499 Get It

Mastocytosis is a rare and heterogeneous group of disorders that may be limited to the skin and even spontaneously regress or may have a systemic presentation with multi-organ involvement and poor outcome. Among the extracutaneous sites, gastrointestinal tract is often affected, but nonspecific clinical manifestations combined with subtle histological findings of the disease makes the diagnosis of gastrointestinal mastocytosis rather hard. In absence of a high index of suspicion, gastrointestinal involvement is easily overlooked. We report a challenging case of systemic mastocytosis presenting with isolated gastrointestinal manifestations without skin involvement, in which the diagnosis was missed at first evaluation of intestinal biopsies.